in this issue
Regions :: Western Europe :: Germany
Merck KGaA and Dr. Reddy’s Partner to Develop and Manufacture Biosimilars
12:03 AM MDT | June 6, 2012 | Deepti Ramesh
Merck KGaA says its Merck Serono division will partner with pharmaceutical company Dr. Reddy’s Laboratories (Hyderabad, India) to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers co-development, manufacturing and commercialization of the compounds around the globe, with some specific country exceptions. Biosimilars are approved versions of innovator biopharmaceutical products after patent expiry. The partnership marks the first step by Merck to enter the biosimilar space...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee